161 related articles for article (PubMed ID: 33283580)
21. Outcome of 3 pregnancies in a patient with chronic myeloid leukemia who received 3 types of tyrosine kinase inhibitors each in different pregnancy: follow-up of the case with a review of published reports.
Alizadeh H; Jaafar H; Kajtár B
Ann Saudi Med; 2015; 35(6):468-71. PubMed ID: 26657232
[TBL] [Abstract][Full Text] [Related]
22. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
23. Outcomes of unplanned tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: retrospective analysis of real-world experience in a single institution.
Iino M; Yamamoto T; Sakamoto Y
Hematology; 2019 Dec; 24(1):355-361. PubMed ID: 30880635
[TBL] [Abstract][Full Text] [Related]
24. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system.
Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E
J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347
[TBL] [Abstract][Full Text] [Related]
25. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
Wong SF; Mirshahidi H
Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
[TBL] [Abstract][Full Text] [Related]
26. Pregnancy: part of life in chronic myelogenous leukemia.
Law AD; Dong Hwan Kim D; Lipton JH
Leuk Lymphoma; 2017 Feb; 58(2):280-287. PubMed ID: 27389567
[TBL] [Abstract][Full Text] [Related]
27. TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.
Valent P; Herndlhofer S; Schneeweiß M; Boidol B; Ringler A; Kubicek S; Gleixner KV; Hoermann G; Hadzijusufovic E; Müllauer L; Sperr WR; Superti-Furga G; Mannhalter C
Oncotarget; 2017 Apr; 8(14):23061-23072. PubMed ID: 28416739
[TBL] [Abstract][Full Text] [Related]
28. [Successful delivery using interferon α for molecular relapse of chronic myeloid leukemia after interruption of tyrosine kinase inhibitor].
Shodai A; Tazaki Y; Uchida N; Hamada T; Akahoshi R; Ueno T; Tabuchi T; Arima N; Hayashida M; Arai A; Nakamura D; Yoshimitsu M; Kobayashi H; Ishitsuka K
Rinsho Ketsueki; 2023; 64(2):102-106. PubMed ID: 36990728
[TBL] [Abstract][Full Text] [Related]
29. [Pregnancy outcome among patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors].
Jiang Q; Jiang B; Chen SS; Jiang H; Qin YZ; Lai YY; Shi HX; Huang XJ
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):6-9. PubMed ID: 22575184
[TBL] [Abstract][Full Text] [Related]
30. Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
Cerveira N; Loureiro B; Bizarro S; Correia C; Torres L; Lisboa S; Vieira J; Santos R; Pereira D; Moreira C; Chacim S; Domingues N; Espírito-Santo A; Oliveira I; Moreira I; Viterbo L; Martins Â; Teixeira MR; Mariz JM
BMC Cancer; 2018 Dec; 18(1):1245. PubMed ID: 30541488
[TBL] [Abstract][Full Text] [Related]
31. WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors.
Haznedaroğlu İC; Kuzu I; İlhan O
Turk J Haematol; 2020 Feb; 37(1):42-47. PubMed ID: 31612694
[TBL] [Abstract][Full Text] [Related]
32. [Delivery of a Healthy Newborn by the Partner of a Patient with CML Undergoing Treatment with Nilotinib].
Aota Y; Udagawa S; Honda T; Okuda Y; Gotoh A
Gan To Kagaku Ryoho; 2020 May; 47(5):811-813. PubMed ID: 32408325
[TBL] [Abstract][Full Text] [Related]
33. The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
Huang W; Luan CH; Hjort EE; Bei L; Mishra R; Sakamoto KM; Platanias LC; Eklund EA
Leukemia; 2016 Jul; 30(7):1502-9. PubMed ID: 26984787
[TBL] [Abstract][Full Text] [Related]
34. [Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China].
Zhu XJ; You Y; Duan MH; Zhu Y; Liu BC; Chen SN; Du X
Zhonghua Xue Ye Xue Za Zhi; 2018 Dec; 39(12):994-997. PubMed ID: 30612400
[No Abstract] [Full Text] [Related]
35. Managing women of childbearing age with chronic myeloid leukemia: safety and treatment considerations.
Robertson HF; Buckton MJ; Apperley JF
Expert Rev Hematol; 2023 May; 16(5):325-332. PubMed ID: 37038615
[TBL] [Abstract][Full Text] [Related]
36. [A Retrospective Analysis of TKI Discontinuation in Patients with CML].
Zhao XL; Hong M; Qiao C; Sun Q; Zhu H; Wang S; Li JY; Qian SX; Zhu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1746-1751. PubMed ID: 34893104
[TBL] [Abstract][Full Text] [Related]
37. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
38. [Effect of nilotinib on pregnancy outcome in female patients with chronic myeloid leukemia].
Zhao HF; Song YP; Li Z; Zhou J; Yu FK; Gui RR; Zu YL; Wei XD; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):986-989. PubMed ID: 32023727
[No Abstract] [Full Text] [Related]
39. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
40. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
